Effect of levothyroxine administration on hemostatic analytes in Doberman Pinschers with von Willebrand disease.
Levothyroxine administration has been suggested to be an effective treatment for canine von Willebrand disease (vWd), but evidence supporting this treatment is lacking. Effects of levothyroxine administration were evaluated in 8 euthyroid Doberman Pinschers with plasma von Willebrand factor (vWf) concentrations < 15%, characteristic of type 1 vWd. Levothyroxine (0.04 mg/kg PO q12h) and placebo were administered for 30 days in a 2-period, 2-treatment, double-blinded, crossover design with a 30-day washout period between treatments. Buccal mucosal bleeding time (BMBT), plasma vWf concentration (vWf: Ag), vWf collagen binding activity (vWf:CBA), factor VIII coagulant activity (FVIII:C), and serum concentrations of total thyroxine (T4), free thyroxine (fT4), 3,5,3'-triiodothyronine (T3), and thyroid-stimulating hormone (TSH) were measured on days 0, 2, and 30 of each treatment period. The 8 dogs (1 male, 7 females) had markedly low plasma vWf:Ag (mean, 8.9%; reference range, 70-180%) and vWf:CBA (mean, 11.1%; reference range, >70%). Response to placebo versus levothyroxine treatment was not significantly different between groups at day 0, 2, or 30 for BMBT, vWf:Ag, vWf:CBA, and FVIII:C. Serum T4, fT4, and T3 concentrations were significantly higher and serum TSH significantly lower in the levothyroxine-treated group than in the placebo group at days 2 and 30. Administration of levothyroxine at 0.04 mg/kg caused laboratory evidence of hyperthyroidism but did not affect plasma FVIII:C and vWf:Ag concentrations or vWf-dependent collagen binding and BMBT. The results of this study failed to identify a direct action of levothyroxine supplementation on plasma vWf concentration or activity in euthyroid Doberman Pinschers with vWd.
Heseltine
Johanna C
JC
Department of Veterinary Clinical Sciences, Oklahoma State University, Stillwater, OK 74078, USA. heselti@okstate.edu
Panciera
David L
DL
Troy
Gregory C
GC
Monroe
William E
WE
Brooks
Marjory B
MB
Feldman
Bernard F
BF
D000818:Animals; D018592:Cross-Over Studies; D004283:Dog Diseases / Q000097:blood / Q000188:drug therapy*; D004285:Dogs; D004311:Double-Blind Method; D005260:Female; D006487:Hemostasis / Q000187:drug effects*; D008297:Male; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood / Q000627:therapeutic use*; D014284:Triiodothyronine / Q000097:blood; D014842:von Willebrand Diseases / Q000097:blood / Q000188:drug therapy / Q000662:veterinary*
D014284:Triiodothyronine; D013972:Thyrotropin; D013974:Thyroxine